Nystatin A3 is a lipid of Polyketides (PK) class. Nystatin a3 is associated with abnormalities such as Mycoses, Candidiasis of the genitals and Gigantism. The involved functions are known as Drug Interactions, Process, Synthesis, Fermentation and Anabolism. Nystatin a3 often locates in Cell membrane, Membrane, Protoplasm, Entire oral cavity and integral to membrane. The associated genes with Nystatin A3 are Gene Clusters. The related lipids are Sterols, 1,2-oleoylphosphatidylcholine, Membrane Lipids, DOPE and N-caproylsphingosine.
To understand associated biological information of Nystatin A3, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Nystatin A3 is suspected in Mycoses, Candidiasis of the genitals, Gigantism and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Nystatin A3
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Woo KY et al. | Peristomal skin complications and management. | 2009 | Adv Skin Wound Care | pmid:20026934 |
Okechukwu DC et al. | Evaluation of the anti-candidal activity of methanolic leaf extract of cleistopholis patens (fam. Annonaceae) on candida species isolated from stage II HIV patients. | 2015 | Afr Health Sci | pmid:26957966 |
Moshi AH et al. | Treatment of oral candidiasis: a study to determine the clinical response of sodium benzoate compared with nystatin suspension. | 1998 | AIDS | pmid:9833873 |
Mukherjee PK et al. | Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants. | 2017 | AIDS | pmid:27677161 |
Selvam MP et al. | Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents. | 1993 | AIDS Res. Hum. Retroviruses | pmid:7686387 |
Goldenberg D et al. | The use of otic powder in the treatment of acute external otitis. | 2002 May-Jun | Am J Otolaryngol | pmid:12019482 |
Rao SP et al. | Candida esophagitis in two children with acute leukemia: successful therapy with ketoconazole. | 1985 | Am J Pediatr Hematol Oncol | pmid:3865555 |
Wolff LJ | Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. Use of prophylactic antibiotics. | 1984 | Am J Pediatr Hematol Oncol | pmid:6393790 |
Berkowitz RJ et al. | Oropharyngeal Candida prophylaxis in pediatric bone marrow transplant patients. | 1985 | Am J Pediatr Hematol Oncol | pmid:3898901 |
Violaris K et al. | Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants. | 2010 | Am J Perinatol | pmid:19504425 |